Oska Health has raised €11 million in seed funding to scale its continuous care model for high-risk, chronically ill patients. The round was led by Capricorn Partners and SwissHealth Ventures, with participation from Revent, Calm Storm, LBBW Venture Capital, BMH, GoHub Ventures, and Aurum Impact.
The new capital will accelerate the expansion of Oska’s AI-powered care infrastructure, which augments care teams and has been supporting chronically ill patients for more than three years.
Oska focuses on multimorbid patients living with multiple chronic conditions such as chronic kidney disease, diabetes, and hypertension. These conditions affect millions of people across Europe and account for a significant share of healthcare spending. The company combines human coaching with AI-enabled care delivery to support chronic patients at scale. Certified health coaches provide continuous support via video calls, chat, and a dedicated digital therapy app, helping translate physicians’ recommendations on lifestyle and dietary changes into daily routines. The aim is to reduce complications and avoidable hospitalizations.
Oska already partners with more than 20 statutory health insurance funds in Germany, offering its service free of charge to insured members. Physicians retain full therapeutic responsibility, while Oska supports implementation in everyday life without requiring additional software or process changes in medical practices.
Investors view the company’s model as a scalable solution to one of healthcare’s most pressing structural challenges: delivering consistent, effective care to high-risk chronic patients between doctor visits.
Chronic diseases continue to place mounting pressure on healthcare systems worldwide. While clinical treatment pathways are often well established, everyday adherence remains a major gap. A significant proportion of chronically ill patients struggle to take medication correctly or sustain lifestyle changes, contributing to reduced quality of life and rising costs. In Germany, a substantial share of healthcare expenditures is attributed to chronically ill populations, and the prevalence of conditions such as chronic kidney disease continues to increase.
Founded in 2022 in Frankfurt, Oska operates in Germany as a certified medical device company. With the fresh funding, the company plans to expand its team, further develop its technological infrastructure, and deepen partnerships with health insurers and physician networks.
KEY QUOTES:
“Chronic diseases cannot be managed in isolated doctor visits; they are decided in everyday life. We combine human support with AI to close this gap. Our technology supports our coaches, reduces administrative burden, and makes high-quality chronic care scalable.”
Niklas Best, CEO And Co-Founder Of Oska Health
“Oska is tackling a structural bottleneck in how healthcare is delivered to chronically ill patients. Over the past years, the team has built an impressive track record in partnering with health insurance funds that use Oska to organize continuous care for chronically ill patients in a medically meaningful and economically sustainable way.”
Antoine D’Hollander, Investment Director At Capricorn Partners
“For us, it is crucial that care has an impact where it has been least effective so far: between doctor visits. Oska has developed a compelling and scalable model to achieve exactly that.”
Markus Rommel, Principal At SwissHealth Ventures
“We have backed Oska Health for over two years now and are thrilled to see their growth rate of >8x, proving what a significant issue they are addressing. We are convinced that their AI-enabled coaching will help not only the millions of people suffering from chronic disease, but our strained health system as a whole.”
Otto Birnbaum, General Partner At Revent
